Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer

Cancer Cell

Volumn 5, Issue 6, 2004, Pages 597-605

  Michalides, Rob ^a   Griekspoor, Alexander ^a   Balkenende, Astrid ^a   Verwoerd, Desiree ^a   Janssen, Lennert ^a   Jalink, Kees ^a   Floore, Arno ^a   Velds, Arno ^a   Van 't Veer, Laura ^a   Neefjes, Jacques ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 2942544830     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.05.016     Document Type: Article

References (40)

1. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer. 2:2002;101-115
2. Bindels E.M., Lallemand F., Balkenende A., Verwoerd D., Michalides R. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene. 21:2002;8158-8165
3. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:2002;243-247
4. Canney P.A., Griffiths T., Latief T.N., Priestman T.F. Clinical significance of tamoxifen withdrawal response. Lancet. 1:1987;36
5. Chen D., Pace P.E., Coombes C., Ali S. Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol. Cell. Biol. 19:1999;1002-1015
6. Forbes J.F. The control of breast cancer. The role of tamoxifen Sem. Oncol. 24(suppl. 1):1997;S1-S5. S1-19
7. Hopp T.A., Fuqua S.A. Estrogen receptor variants. J. Mammary Gland Biol. Neoplasia. 3:1998;73-83
8. Hordijk P.L., Verlaan I., Jalink K., Van Corven E.J., Moolenaar W.H. cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J. Biol. Chem. 269:1994;3534-3538
9. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen- resistant breast cancer. Lancet. 345:1995;29-30
10. Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., Morris C. Fulvestrant, formerly 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20:2002;3396-3403
11. Hughes T.R., Marton M.J., Jones A.R., Roberts C.J., Stoughton R., Armour C.D., Bennett H.A., Coffey E., Dai H., He Y.D., et al. Functional discovery via a compendium of expression profiles. Cell. 102:2000;109-126
12. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494
13. Kraus W.L., McInerney E.M., Katzenellenbogen B.S. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. USA. 92:1995;12314-12318
14. Le Goff P., Montano M.M., Schodin D.J., Katzenellenbogen B.S. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem. 269:1994;4458-4466
15. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily. the second decade Cell. 83:1995;835-839
16. Metivier R., Stark A., Flouriot G., Hubner M.R., Brand H., Penot G., Manu D., Denger S., Reid G., Kos M., et al. A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol. Cell. 10:2002;1019-1032
17. Michalides R., van Tinteren H., Balkenende A., Vermorken J.B., Benraadt J., Huldij J., van Diest P. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer. 86:2002;402-408
18. Miller W.R., Hulme M.J., Bartlett J.M., MacCallum J., Dixon J.M. Changes in messenger RNA expression of protein kinase A regulatory subunit alpha in breast cancer patients treated with tamoxifen. Clin. Cancer Res. 3:1997;2399-2404
19. Norris R.M., Paige L.A., Christensen D.J., Chang C.Y., Huacani M.R., Fan D., Hamilton P.T., Fowlkes D.W., Mc Donnell D.P. Peptide antagonists of the human estrogen receptor. Science. 285:1999;744-746
20. O'Regan R.M., Jordan V.C. The evolution of tamoxifen therapy in breast cancer. Selective oestrogen-receptor modulators and downregulators Lancet Oncol. 3:2002;207-214
21. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., Manning D.L., Nicholson R.I. Comparison of the effects of a pure steroidal anti-estrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 87:1995;746-750
22. Osborne C.K., Zhao H., Fuqua S.A. Selective estrogen receptor modulators. Structure, function, and clinical use J. Clin. Oncol. 18:2000;3172-3186
23. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy. Results of a North American trial J. Clin. Oncol. 20:2002;3386-3395
24. Park W.C., Jordan V.C. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol. Med. 8:2002;82-88
25. Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L., Gorman C.M., Parker M.G., Sliwkowski M.X., Slamon D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:1995;2435-2446
26. Pike A.C.W., Brzozowski M., Walton J., Hubbard R.E., Thorsell A., Li Y., Gustafsson J., Carlquist M. Structural insights into the mode of action of a pure anti-estrogen. Structure (Camb.). 9:2001;145-153
27. Planas-Silva M.D., Donaher J.L., Weinberg R.A. Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression. Cancer Res. 59:1999;4788-4792
28. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 295:2002;2465-2468
29. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937
30. Smith C.L., Onate S., Tsai M., O'Malley B.W. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. USA. 93:1996;8884-8888
31. Trowbridge J.M., Rogatsky I., Garabedian M.J. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc. Natl. Acad. Sci. USA. 94:1997;10132-10137
32. van der Wal J., Habets R., Varnai P., Balla T., Jalink K. Monitoring agonist-induced phospholipase C activation in live cells by fluorescence resonance energy transfer. J. Biol. Chem. 276:2001;15337-15344
33. van Ham S.M., Tjin E.P., Lillemeier B.F., Gruneberg U., van Meijgaarden K.E., Pastoors L., Verwoerd D., Tulp A., Canas B., Rahman D., et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr. Biol. 7:1997;950-957
34. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Okay K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
35. Wagner B.L., Norris J.D., Knotts T.A., Weigel N.L., McDonnel D.P. The nuclear corepressors NCor and SMRT are key regulators of both ligand-and 8-bromo-cyclic-AMP dependent transcriptional activity of the human progesterone receptor. Mol. Cell. Biol. 18:1998;1369-1378
36. Yang Y., Germann C.H., Arlinghaus R.B., Singh B. Inhibition of v-Mos kinase activity by protein kinase A. Mol. Cell. Biol. 16:1996;800-809
37. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., Speed T.P. Normalization for cDNA microarray data. a robust composite method addressing single and multiple slide systematic variation Nucl. Acid Res. 30:2002;e15
38. Zhang J., Campbell R.E., Ting A.Y., Tsien R.Y. Creating new fluorescent probes for cell biology. Nat. Rev. Mol. Cell Biol. 3:2002;906-918
39. Zwijsen R.M., Wientjens E., Klompmaker R., van der Sman J., Bernards R., Michalides R.J. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 88:1997;405-415
40. Zwijsen R.M., Buckle R.S., Hijmans E.M., Loomans C.J., Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 12:1998;3488-3498